吉西他滨联合铂类治疗铂类耐药复发性卵巢癌的临床研究

Clinical Study of Gemcitabine Combined with Platinum in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

目的:探究吉西他滨联合铂类治疗铂类耐药复发性卵巢癌临床效果。方法:选择2016年1月~2019年1月某院收治的25例铂类耐药复发性卵巢癌患者,依照随机数字表法将其分为观察组13例与对照组12例。对照组患者给予吉西他滨治疗,观察组实施吉西他滨联合奥沙利铂治疗,比较组间患者治疗有效率与不良反应情况。结果:观察组治疗总有效率76.9%显著高于对照组治疗总有效率50%,差异具有统计学意义(P<0.05);观察组不良反应中无4级不良反应,3级不良反应为3级白细胞减少1例,3级中立性白细胞减少1例,3级肝脏病毒1例,3级恶心呕吐1例,对照组4级白细胞减少1例,4级恶心呕吐1例,3级中立性白细胞减少3例,3级肝脏病毒3例,神经毒性1例,腹泻1例,对照组整体不良反应明显高于观察组,差异有统计学意义(P<0.05)。结论:吉西他滨联合奥沙利铂治疗铂类耐药复发性卵巢癌效果显著,有效提升治疗效果,降低不良反应。

Objective:To explore the clinical effect of gemcitabine combined with platinum in the treatment of platinum-resistant recurrent ovarian cancer.Methods:From January 2016 to January 2019,25 patients with platinum-resistant recurrent ovarian cancer were divided into observation group and control group,with 13 cases in observation group and 12 cases in control group according to random number table method.Patients in the control group were treated with gemcitabine,while patients in the observation group were treated with gemcitabine combined with oxaliplatin.The efficacy and adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 76.9%,which was significantly higher than that of the control group(50%,P<0.05).There was no grade 4 adverse reactions in the observation group,and there was 1 case of grade 3 leukopenia,1 case of grade 3 neutral leukopenia in,1 case of grade 3 hepatitis virus,and 1 case of grade 3 nausea and vomiting in grade 3 adverse reactions in the observation group.There was 1 case of grade 4 leukopenia,1 case of grade 4 nausea and vomiting,3 cases of grade 3 neutral leukopenia,3 cases of grade 3 hepatitis virus,1 case of neurotoxicity and 1 case of diarrhea in the control group.The overall adverse reactions in the control group were significantly higher than those in the observation group(P<0.05).Conclusion:Gemcitabine combined with oxaliplatin is effective in the treatment of platinum-resistant recurrent ovarian cancer,which can effectively improve the therapeutic effect and reduce adverse reactions.